<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255186</url>
  </required_header>
  <id_info>
    <org_study_id>448 kHz CRMRF UCLM</org_study_id>
    <nct_id>NCT04255186</nct_id>
  </id_info>
  <brief_title>Treatment Using 448 kHz CRMRF in Subacromial Syndrome.</brief_title>
  <acronym>CRMRF</acronym>
  <official_title>Treatment Using 448 kHz Capacitive Resistive Monopolar Radiofrequency in Patients With Subacromial Syndrome. A Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Nuestra Se침ora del Prado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Castilla-La Mancha Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiba S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Castilla-La Mancha</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of 448 kHz capacitive resistive&#xD;
      monopolar radiofrequency in the treatment of subacromial syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shoulder pain has a high prevalence in our society, several studies estimate an annual&#xD;
      prevalence between 5% and 47%. It is one of the main causes of musculoskeletal pain,&#xD;
      particularly in third place, after the low back pain and neck pain.&#xD;
&#xD;
      Symptoms of pathologies of subacromial syndrome, where, regardless of origin, pain is the&#xD;
      number one symptom for the patient, which emanates functional impairment and the impact on&#xD;
      quality of life.&#xD;
&#xD;
      Among the non-pharmacological treatments of subacromial syndrome, a systematic review&#xD;
      concludes that the first line of intervention should be a therapeutic exercise program. In&#xD;
      many cases, this is usually accompanied by the application of electrophysical agents (short&#xD;
      wave, laser, etc.). A recent study has shown that the application of Short Wave Radio&#xD;
      Frequency improved pain in people with subacromial syndrome. The current frequency that is&#xD;
      applied in the short wave is 27.12 MHz, however, there are other relatively new forms of&#xD;
      radiofrequency in which a frequency less than 1 MHz is used. These are beginning to be used&#xD;
      in clinical practice and recently have shown positive results related to pain and&#xD;
      functionality of musculoskeletal pathologies such as knee osteoarthritis. In these two&#xD;
      clinical trials, what is called Resistive Capacitive Monopolar Radio Frequency (RFCR) was&#xD;
      used, the frequency of which was 448 KHz and 485KHz respectively, much lower than the&#xD;
      frequency used in Shortwave. The RFCR has a potential advantage since it is applied with&#xD;
      electrodes directly on the skin and is not transmitted in the air unlike the Short Wave.&#xD;
&#xD;
      Based on the few clinical trials in people with pathology and the physiological effects&#xD;
      evidenced in healthy people and in vitro preclinical studies, it is considered pertinent to&#xD;
      carry out the present investigation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Actual">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>minimun 0 - maximun10. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>minimun 0 - maximun10. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>1 month after the end of the intervention</time_frame>
    <description>minimun 0 - maximun10. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>minimun 0 - maximun10. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPADI</measure>
    <time_frame>Baseline</time_frame>
    <description>Shoulder Pain and Disabilty Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPADI</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>Shoulder Pain and Disabilty Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPADI</measure>
    <time_frame>1 month after the end of the intervention</time_frame>
    <description>Shoulder Pain and Disabilty Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPADI</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>Shoulder Pain and Disabilty Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick DASH</measure>
    <time_frame>Baseline</time_frame>
    <description>Abbreviated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick DASH</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>Abbreviated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick DASH</measure>
    <time_frame>1 month after the end of the intervention</time_frame>
    <description>Abbreviated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick DASH</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>Abbreviated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPT</measure>
    <time_frame>Baseline</time_frame>
    <description>Pressure Pain Threshold in subacromial area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPT</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>Pressure Pain Threshold in subacromial area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality ol life - 5 dimensions (EQ-5D)</measure>
    <time_frame>Baseline</time_frame>
    <description>Higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality ol life - 5 dimensions (EQ-5D)</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>Higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality ol life - 5 dimensions (EQ-5D)</measure>
    <time_frame>1 month after the end of the intervention</time_frame>
    <description>Higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality ol life - 5 dimensions (EQ-5D)</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>Higher scores mean a better outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Medication intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Analgesic ladder for chronic pain. Higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication intake</measure>
    <time_frame>After 3 weeks</time_frame>
    <description>Analgesic ladder for chronic pain. Higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication intake</measure>
    <time_frame>1 month after the end of the intervention</time_frame>
    <description>Analgesic ladder for chronic pain. Higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication intake</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>Analgesic ladder for chronic pain. Higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Blinding assesment</measure>
    <time_frame>After three weeks</time_frame>
    <description>The patient, the external evaluator, the therapist who applies radiofrequency and the kinesitherapist physiotherapist will be asked about the patient's group of belonging.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blinding assesment</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>The patient, the external evaluator, the therapist who applies radiofrequency and the kinesitherapist physiotherapist will be asked about the patient's group of belonging.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total number of sessions of the exercise protocol for discharge</measure>
    <time_frame>3 months after the end of the intervention</time_frame>
    <description>After the first 3 weeks, if the patient has not met the criteria for discharge, more sessions will continue performing the same exercise protocol according to medical criteria. This total number of sessions will be recorded.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Shoulder Impingement Syndrome</condition>
  <condition>Subacromial Impingement Syndrome</condition>
  <arm_group>
    <arm_group_label>Thermal CRMRF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 35 VA in capacitive method (10% of the maximum power of the equipment) and 30 W in the resistive method (15% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).&#xD;
In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subthermal CRMRF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham CRMRF</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency</intervention_name>
    <description>Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method</description>
    <arm_group_label>Thermal CRMRF</arm_group_label>
    <other_name>CRMRF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency</intervention_name>
    <description>Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method</description>
    <arm_group_label>Subthermal CRMRF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <description>a simulated stimulation protocol so that the device does not emit current</description>
    <arm_group_label>Sham CRMRF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 70 years years old with diagnosis of subacromial syndrome&#xD;
&#xD;
          -  Visual Analogue Scale (VAS) less than or equal to 7.&#xD;
&#xD;
          -  Positive Neer and Hawkins test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical examination compatible with complete rotator cuff tear (Drop-arm positive&#xD;
             test)&#xD;
&#xD;
          -  Fibromyalgia&#xD;
&#xD;
          -  Adhesive capsulitis&#xD;
&#xD;
          -  Be receiving physiotherapeutic treatment or have received it previously for this&#xD;
             pathology one month before the start of treatment.&#xD;
&#xD;
          -  Patients with alterations of thermal sensitivity.&#xD;
&#xD;
          -  Derived from the absolute and relative contraindications of CRMRF:&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Thrombophlebitis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Skin disorders (recent wounds or burns)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Avenda침o-Coy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Castilla La Mancha University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Aceituno-G칩mez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Castilla-La Mancha Health Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario Nuestra Se침ora del Prado</name>
      <address>
        <city>Talavera de la Reina</city>
        <state>Toledo</state>
        <zip>45600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>shoulder pain</keyword>
  <keyword>shoulder impingement syndrome</keyword>
  <keyword>radiofrequency treatment</keyword>
  <keyword>electrophysical agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Impingement Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

